Aldosterone-induced endothelial dysfunction of rat aorta: Role of poly(ADP-ribose) activation

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 10, Issue 3, 2009, Pages 127-137

  Tasatargil, Arda ^a   Tekcan, Merih ^a   Celik Ozenci, Ciler ^a   Ece Gungor, Nazli ^a   Dalkiran, Bedriniam ^a  

^a AKDENIZ UNIVERSITY   (Turkey)

Author keywords

Aldosterone; Aorta; Endothelial dysfunction; PARPA

Indexed keywords

1,5 ISOQUINOLINEDIOL; ACETYLCHOLINE; ALDOSTERONE; ISOQUINOLINE DERIVATIVE; N (5,6 DIHYDRO 6 OXO 2 PHENANTHRIDINYL) 2 DIMETHYLAMINOACETAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 2; NITROPRUSSIDE SODIUM; POLY(ADENOSINE DIPHOSPHATE RIBOSE); UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; ENZYME ACTIVATION; HEART RATE; IMMUNOHISTOCHEMISTRY; ISOMETRICS; MALE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; SYSTOLIC BLOOD PRESSURE; TELEMETRY; THORACIC AORTA; VASODILATATION;

ACETYLCHOLINE; ALDOSTERONE; ANIMALS; AORTA, THORACIC; APOPTOSIS; BLOOD PRESSURE; ENDOTHELIUM, VASCULAR; ENZYME ACTIVATION; ENZYME INHIBITORS; HEART RATE; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; ISOPROTERENOL; MALE; NITROPRUSSIDE; PHENANTHRENES; POLY(ADP-RIBOSE) POLYMERASES; RATS; RATS, WISTAR; VASODILATION;

EID: 69849102868     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.1177/1470320309343655     Document Type: Article

References (45)

1. Giebisch G. Renal potassium transport: Mechanisms and regulation. Am J Physiol 1998;274:F817-33.
2. Giebisch G., Wang W. Renal tubule potassium channels: Function, regulation and structure. Acta Physiol Scand 2000;170:153-73.
3. Palmer LG Potassium secretion and the regulation of distal nephron K channels. Am J Physiol 1999;277:F821-5.
4. Palmer LG, Frindt G. Aldosterone and potassium secretion by the cortical collecting duct. Kidney Int 2000;57:1324-8.
5. Schiffrin EL Effects of aldosterone on the vasculature. Hypertension 2006;47:312-18.
6. Takeda Y., Yoneda T., Demura M., Miyamori I., Mabuchi H. Cardiac aldosterone production in genetically hypertensive rats. Hypertension 2000;36:495-500.
7. Funder JW Mineralocorticoid receptors and cardiovascular damage: It's not just aldosterone. Hypertension 2006;47:634-5.
8. Hashikabe Y., Suzuki K., Jojima T., Uchida K., Hattori Y. Aldosterone impairs vascular endothelial cell function. J Cardiovasc Pharmacol 2006;47:609-13.
9. Safar ME Systolic hypertension in the elderly: Arterial wall mechanical properties and the renin-angiotensin-aldosterone system. J Hypertens 2005;23:673-81.
10. Cachofeiro V., Miana M., de Las Heras N. et al. Aldosterone and the vascular system. J Steroid Biochem Mol Biol 2008;109:331-5.
11. Oberleithner H., Ludwig T., Riethmuller C. et al. Human endothelium: target for aldosterone. Hypertension 2004;43:952-6.
12. Skøtt O., Uhrenholt TR, Schjerniog J., Hansen PBL, Rasmussen LE, Jensen BL Rapid actions of aldosterone in vascular health and disease - friend or foe? Pharmacol Ther 2006;2:495-507.
13. Golestaneh N., Klein C., Valamanesh F., Suarez G., Agarwal MK, Mirshahi M. Mineralocorticoid receptor-mediated signaling regulates the ion gated sodium channel in vascular endothelial cells and requires an intact cytoskeleton. Biochem Biophys Res Commun 2001;80:1300-06.
14. Oberleithner H., Riethmuller C., Ludwig T. et al. Differential action of steroid hormones on human endothelium. J Cell Sci 2006;119:1926-32.
15. Oberleithner H. Is the vascular endothelium under the control of aldosterone? Facts and hypothesis. Pflugers Arch Eur J Physiol 2007;454:187-93.
16. Dworakowski R., Alom-Ruiz SP, Shah AM NADPH oxidase-derived reactive oxygen species in the regulation of endothelial phenotype. Pharmacol Rep 2008;60:21-3.
17. Farquharson CA, Struthers AD Aldosterone induces acute endothelial dysfunction in vivo in humans: Evidence for an aldosterone-induced vasculopathy. Clin Sci 2002;103:425-31.
18. Virdis A., Neves MF, Amir F., Viel E., Touyz RM, Schiffrin EL Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension 2002;40:504-10.
19. Blanco-Rivero J., Cachofeiro V., Lahera V. et al. Participation of prostacyclin in endothelial dysfunction induced by aldosterone in normotensive and hypertensive rats. Hypertension 2005;46:107-12.
20. Freel EM, Connell JM Mechanisms of hypertension: The expanding role of aldosterone. J Am Soc Nephrol 2004;15:1993-2001.
21. Funder JW Non-genomic actions of aldosterone: Role in hypertension. Curr Opin Nephrol Hypertens 2001;10:227-30.
22. Münzel T., Just H., Harrison DG The physiology and pathophysiology of the nitric oxide/superoxide system. In: Born GVR and Schwartz CJ (eds.). Vascular Endothelium: Physiology, Pathology and Therapeutic Options. Stuttgart: Schattauer, 1997;205-20.
23. Radovits T., Lin LN, Zotkina J. et al. Poly(ADP-ribose) polymerase inhibition improves endothelial dysfunction induced by reactive oxidant hydrogen peroxide in vitro. Eur J Pharmacol 2007;564:158-66.
24. Berger NA Poly (ADP-ribose) in the cellular response to DNA damage. Radic Res 1985;101:4-15.
25. Pacher P., Liaudet L., Bai P. et al. Activation of poly (ADP-ribose) polymerase contributes to development of doxorubicininduced heart failure. J Pharmacol Exp Ther 2002;300:862-7.
26. Schraufstatter IU, Hinshaw DB, Hyslop PA, Spragg RG, Cochrane CG DNA strand breaks activate poly adenosine diphosphate-ribose polymerase and lead to depletion of nicotinamide adenine dinucleotide. J Clin Invest 1986;77:1312-20.
27. Eliasson MJ, Sampei K., Mandir AS et al. Poly (ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia. Nat Med 1997;3:1089-95.
28. Liaudet L., Soriano FG, Szabo E. et al. Protection against hemorrhagic shock in mice genetically deficient in poly (ADP-ribose) polymerase. Proc Natl Acad Sci U S A 2000;97:10203-08.
29. Pacher P., Mabley JG, Soriano FG, Liaudet L., Komjati K., Szabo C. Endothelial dysfunction in aging animals: The role of poly (ADP-ribose) polymerase activation. Br J Pharmacol 2002;135:1347-50.
30. Pacher P., Liaudet L., Soriano FG, Mabley JG, Szabo E., Szabo C. The role of poly (ADP-ribose) polymerase in the development of cardiovascular dysfunction in diabetes mellitus. Diabetes 2002;51:514-21.
31. Tasatargil A., Dalaklioglu S., Sadan G. Poly (ADP-ribose) polymerase inhibition prevents homocysteine-induced endothelial dysfunction in isolated rat aorta. Pharmacology 2004;72:99-105.
32. Tasatargil A., Dalaklioglu S., Sadan G. Inhibition of poly(ADP-ribose) polymerase prevents vascular hyporesponsiveness induced by lipopolysaccharide in isolated rat aorta. Pharmacol Res 2005;51:581-6.
33. Tasatargil A., Aksoy NH, Dalaklioglu S., Sadan G. Poly (ADP-ribose) polymerase as a potential target for the treatment of acute renal injury caused by lipopolysaccharide. Ren Fail 2008;30:115-20.
34. Zingarelli B., Salzman AL, Szabo C. Genetic disruption of poly (ADP-ribose) synthetase inhibits the expression of P-selectin and intracellular adhesion molecule-1 in myocardial ischemia/reperfusion injury. Circ Res 1998;83:85-94.
35. Duprez D., De Buyzere M., Rietzschel ER, Clement DL Aldosterone and vascular damage. Curr Hypertens Rep 2000;2:327-34.
36. Nishizaka MK, Zaman MA, Green SA, Renfroe KY, Calhoun DA Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism. Circulation 2004;109:2857-61.
37. Pu Q., Neves MF, Virdis A., Touyz RM, Schiffrin EL Endothelin antagonism on aldosterone-induced oxidative stress and vascular remodeling. Hypertension 2003;42:49-55.
38. Ahokas RA, Warrington KJ, Gerling IC et al. Aldosteronism and peripheral blood mononuclear cell activation: A neuroendocrine-immune interface. Circ Res 2003;93:e124-35.
39. Iglarz M., Touyz RM, Viel EC, Amiri F., Schiffrin EL Involvement of oxidative stress in the profibrotic action of aldosterone interaction with the renin-angiotensin system. Am J Hypertens 2004;17:597-603.
40. Virag L., Szabo C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev 2002;54:375-429.
41. Garcia Soriano F., Virag L., Jagtap P. et al. Diabetic endothelial dysfunction: The role of poly(ADP-ribose) polymerase activation. Nat Med 2001;7:108-13.
42. Pieper AA, Walles T., Wei G. et al. Myocardial postischemic injury is reduced by poly (ADP-ribose) polymerase-1 gene disruption. Mol Med 2000;6:271-82.
43. Yamamoto M., Hara H., Adachi T. Effects of homocysteine on the binding of extracellular-superoxide dismutase to the endothelial cell surface. FEBS Lett 2000;486:159-62.
44. Szabo C., Cuzzocrea S., Zingarelli B., O'Connor M., Salzman AL Endothelial dysfunction in a rat model of endotoxic shock. Importance of the activation of poly (ADP-ribose) synthetase by peroxynitrite. J Clin Invest 1997;100:723-35.
45. Soriano FG, Virag L., Szabo C. Diabetic endothelial dysfunction: Role of reactive oxygen and nitrogen species production and poly(ADP-ribose) polymerase activation. J Mol Med 2001;79:437-48.